Haematologica
HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by de Fijter, C.
Right arrow Articles by Donker, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by de Fijter, C.
Right arrow Articles by Donker, A.
Haematologica, Vol 80, Issue 4, 332-334
Copyright © 1995 by Ferrata Storti Foundation

Clinical Trial

Does additional treatment with fish oil mitigate the side effects of recombinant human erythropoietin in dialysis patients?

CW de Fijter, C Popp-Snijders, LP Oe, DD Tran, J van der Meulen, and AJ Donker

Department of Internal Medicine, Free University Hospital, Amsterdam, The Netherlands.

Since fish oil has been reported to reduce platelet aggregability, to reduce blood viscosity by increasing red blood cell deformability and to lower blood pressure, we studied the effect of dietary supplementation with fish oil on the occurrence of adverse effects in patients receiving recombinant human erythropoietin (rHuEPO). In a prospective, randomized, double blind cross-over design we studied the effect of daily ingestion of 3 g fish oil versus 3 g corn oil (placebo) for 5 months, with a wash-out period of 3 months in between. Thirty-two dialysis patients newly treated with rHuEPO participated. rHuEP0 was given using a low and slow dose regimen (25 U/kg twice weekly s.c.). Target Hct was 35%. Blood pressure, red blood cell deformability, plasma viscosity, fatty acid composition of plasma phospholipids, and fibrinogen levels were measured at 0, 5, 8 and 13 months. In both groups a stable target Hct (35%) was reached within 3 months. Blood pressure was not significantly different between the groups at any time point. In 4 patients (2 on fish oil and 2 on placebo) antihypertensives had to be increased to regulate blood pressure adequately, whereas shunt occlusion occurred in one patient on placebo. Despite a significant increase in the omega-3 fatty acid content of plasma phospholipids during ingestion of fish oil, no significant changes in red blood cell deformability were observed. Since hypertension and shunt occlusion occurred at rates comparable to those reported in the literature, long-term ingestion of fish oil does not appear to mitigate the side effects of low and slow dose rHuEPO.


This article has been cited by other articles:


Home page
 CJASNHome page
A. Friedman and S. Moe
Review of the Effects of Omega-3 Supplementation in Dialysis Patients
Clin. J. Am. Soc. Nephrol., March 1, 2006; 1(2): 182 - 192.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
Copyright © 1995 by the Ferrata Storti Foundation.